期刊文献+

Single center experience with intrathoracic impedance monitoring in chronic heart failure patients

Single center experience with intrathoracic impedance monitoring in chronic heart failure patients
原文传递
导出
摘要 Background The Medtronic InSync Sentry is the first available cardiac resynchronization therapy defibrillator (CRT-D)which can monitor fluid status by measuring intrathoracic impedance. This study was designed to observe the effectiveness of intrathoracic impedance monitoring on detecting aggravation of heart failure.Methods We retrospectively analyzed the clinical data of 14 consecutive patients. Patients were regularly followed up every 3-6 months after the implantation. At each visit, interrogation of the device was done. Patients were instructed to inform the researcher on hearing the device alert, and to take extra 40 milligrams of furosemidum if they had aggravated symptoms later. If the symptoms could not be relieved, they were asked to see a doctor. Data about heart failure hospitalization were collected from the medical record.Results During 18-48 months follow-up, a total of 7 patients encountered 28 alert events. On one hand, alert events appeared before all deteriorated symptoms and heart failure hospitalizations. On the other hand, there were 23 alerts followed by deterioration of heart failure symptoms, and 2 alerts related to 2 hospitalizations caused by pulmonary infection in one patient. Only 5 patients were hospitalized 10 times for deterioration of cardiac function.Conclusion The function of intrathoracic impedance monitoring is reliable in predicting deterioration of heart failure. Background The Medtronic InSync Sentry is the first available cardiac resynchronization therapy defibrillator (CRT-D)which can monitor fluid status by measuring intrathoracic impedance. This study was designed to observe the effectiveness of intrathoracic impedance monitoring on detecting aggravation of heart failure.Methods We retrospectively analyzed the clinical data of 14 consecutive patients. Patients were regularly followed up every 3-6 months after the implantation. At each visit, interrogation of the device was done. Patients were instructed to inform the researcher on hearing the device alert, and to take extra 40 milligrams of furosemidum if they had aggravated symptoms later. If the symptoms could not be relieved, they were asked to see a doctor. Data about heart failure hospitalization were collected from the medical record.Results During 18-48 months follow-up, a total of 7 patients encountered 28 alert events. On one hand, alert events appeared before all deteriorated symptoms and heart failure hospitalizations. On the other hand, there were 23 alerts followed by deterioration of heart failure symptoms, and 2 alerts related to 2 hospitalizations caused by pulmonary infection in one patient. Only 5 patients were hospitalized 10 times for deterioration of cardiac function.Conclusion The function of intrathoracic impedance monitoring is reliable in predicting deterioration of heart failure.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第14期2219-2221,共3页 中华医学杂志(英文版)
基金 This study was supported by the grants from the National Natural Science Foundation of China (No. 30770860), the National Key Basic Research Program of China (No. 2007CB512105) and China Health & Medical Development Foundation (No. 2008-zhFj1).
关键词 heart failure intrathoracic impedance cardiac resynchronization therapy defibrillator heart failure intrathoracic impedance cardiac resynchronization therapy defibrillator
  • 相关文献

参考文献9

  • 1Wang L.Fundamentals of intrathoracie impedance monitoring in heart failure.Am J Cardiol 2007; 99 (10A):3G-10G.
  • 2Luthje L,Drescher T,Zenker D,Vollmarm D.Detection of heart failure de,compensation using intrathoracic impedance monitoring by a triple-chamber implantable defibrillator.Heart Rhythm 2005; 2:997-999.
  • 3Stewart S,Jenkins A,Buchan S,McGuire A,Capewell S,McMurray JJ.The current cost of heart failure to the National Health Service in the UK.Eur J Heart Fail 2002; 4:361-371.
  • 4Lewin J,Ledwidge M,O'Loughlin C,McNally C,McDonald K.Clinical deterioration in established heart failure:what is the value of BNP and weight gain in aiding diagnosis? Eur J Heart Fail 2005; 7:953-957.
  • 5Yu CM,Wang L,Chau E,Chan RH,Kong SL,Tang MO,et al.Intrathoracic impedance monitoring in patients with heart failure:correlation with fluid status and feasibility of early warning preceding hospitalization.Circulation 2005; 112:841-848.
  • 6Vollmann D,N(a)gele H,Schauerte P,Wiegand U,Butter C,Zanotto G,et al.Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure.Eur Heart J 2007; 28:1835-1840.
  • 7Small RS,Wickemeyer W,Germany R,Hoppe B,Andrulli J,Brady PA,et al.Changes in intrathoracic impedance are associated with subsequent risk of hospitalizations for acute decompensated heart failure:clinical utility of implanted device monitoring without a patient alert.J Card Fail 2009;15:475-481.
  • 8Catanzariti D,Lunati M,Landolina M,Zanotto G,Lonardi G,Iacopino S,et al.Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure.Pacing Clin Electrophysiol 2009; 32:363-370.
  • 9Braunschweig F,Ford I,Conraads V,Cowie MR,Jondeau G,Kautzner J,et al.Can monitoring of intrathoracic impedance reduce morbidity and mortality in patients with chronic heart failure? Rationale and design of the Diagnostic Outcome Trial in Heart Failure (DOT-HF).Eur J Heart Fail 2008; 10:907-916.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部